Literature DB >> 6601061

Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.

C Chu, R Schneerson, J B Robbins, S C Rastogi.   

Abstract

Conjugates were prepared by carbodiimide-mediated coupling of adipic acid hydrazide derivatives of Haemophilus influenzae type b (Hib), Escherichia coli K100, and pneumococcal 6A (Pn6A) polysaccharides with tetanus toxoid (TT), as an example of a "useful" carrier, and horseshoe crab hemocyanin (HCH), as an example of a "nonsense" carrier. These conjugates were injected into NIH mice, and their serum antibody responses to the polysaccharides and proteins were characterized. As originally reported, Hib conjugates increased the immunogenicity of the capsular polysaccharide and elicited greater than the estimated protective levels of anti-Hib antibodies in most recipients after one injection and in all after the third injection (Schneerson et al., J. Exp. Med. 152:361-376, 1980). Both Hib conjugates induced similar anti-Hib responses. The K100-HCH conjugate was more immunogenic than the K100-TT conjugate and elicited anti-Hib responses similar to the Hib conjugates after the third injection. Simultaneous injection of the K100 and the Hib conjugates did not enhance the anti-Hib response. The Pn6A-TT conjugate induced low levels of anti-Hib antibodies; when injected simultaneously with the Hib conjugates, the anti-Hib response was enhanced, as all mice responded after the first injection and with higher levels of anti-Hib than observed with the Hib conjugates alone (P < 0.05). The Pn6A conjugates were not as immunogenic as the Hib conjugates. Pn6A-TT was more effective than was Pn6A-HCH; it elicited anti-Pn6A (>100 ng of antibody nitrogen per ml) in 6 of 10 mice after the third injection. The addition of the Hib-HCH conjugate to the Pn6A-TT conjugate increased the anti-Pn6A response with a higher geometric mean antibody titer, and 9 of 10 mice responded after the third injection. A preparation of diphtheria toxoid, TT, and pertussis vaccine increased the anti-Hib antibody levels after the first injection only in mice receiving Hib-TT, but not in mice receiving Hib-HCH, suggesting that additional carrier protein (TT) enhanced the anti-polysaccharide response. Simultaneous injection of Hib and Pn6A conjugates with the same or different carriers resulted in an enhanced serum antibody response to each polysaccharide. The anti-tetanus toxin response reached protective levels (>0.01 U/ml) in most mice after the first injection and in all mice after the second and third injections of TT conjugates. A progressive increase in the anti-HCH response with each additional injection was noted in animals receiving HCH conjugates. Animals receiving the diphtheria toxoid-TT-pertussis vaccine preparation responded with a greater increase in anti-carrier antibody than those receiving the conjugates alone. This method of synthesis provided conjugates capable of inducing protective levels of antibodies to both the polysaccharides and carrier proteins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601061      PMCID: PMC264842          DOI: 10.1128/iai.40.1.245-256.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  The effect of Bordetella pertussis on the antibody response in mice to type III pneumococcal polysaccharide.

Authors:  A S Kong; S I Morse
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

2.  The bacteriology of pneumococcal otitis media.

Authors:  R Austrian; V M Howie; J H Ploussard
Journal:  Johns Hopkins Med J       Date:  1977-09

3.  Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.

Authors:  G R Siber; S A Weitzman; A C Aisenberg; H J Weinstein; G Schiffman
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

4.  Semi-synthetic vaccines composed of capsular polysaccharides of pathogenic bacteria covalently bound to proteins for the prevention of invasive diseases.

Authors:  R Schneerson; J E Robbins; C Y Chu; A Sutton; G Schiffman; W F Vann
Journal:  Prog Allergy       Date:  1983

5.  Age-related response to two Haemophilus influenzae type b vaccines.

Authors:  D J Pincus; D Morrison; C Andrews; E Lawrence; S H Sell; P F Wright
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

6.  Modification of antibody response to type III pneumopolysaccharide by route of injection of pertussis vaccine.

Authors:  R S Speirs; R W Benson; D W Roberts
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

7.  The Protective or Curative Element in Type B H. influenzae Rabbit Serum.

Authors:  H E Alexander; M Heidelberger; G Leidy
Journal:  Yale J Biol Med       Date:  1944-05

8.  Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b.

Authors:  P Anderson; G Peter; R B Johnston; L H Wetterlow; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

9.  Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.

Authors:  H Peltola; H Käyhty; A Sivonen; H Mäkelä
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

10.  THE ACTION OF TYPE-SPECIFIC HEMOPHILUS INFLUENZAE ANTISERUM.

Authors:  M Pittman
Journal:  J Exp Med       Date:  1933-11-30       Impact factor: 14.307

View more
  46 in total

1.  Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.

Authors:  S C Szu; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

2.  Important science--it's all about the SPIN.

Authors:  Arturo Casadevall; Ferric C Fang
Journal:  Infect Immun       Date:  2009-07-27       Impact factor: 3.441

3.  Use of immuno assays during the development of a Hemophilus influenzae type b vaccine for technology transfer to emerging vaccine manufacturers.

Authors:  Ahd Hamidi; Hans Kreeftenberg
Journal:  Hum Vaccin Immunother       Date:  2014-11-13       Impact factor: 3.452

4.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

5.  Cloning and surface expression in Escherichia coli of a structural gene encoding a surface protein of Haemophilus influenzae type b.

Authors:  P L Holmans; T A Loftus; E J Hansen
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

6.  Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis.

Authors:  G R Siber; D M Ambrosino; J McIver; T J Ervin; G Schiffman; S Sallan; G F Grady
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

7.  Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer.

Authors:  Ahd Hamidi; Pauline Verdijk; Hans Kreeftenberg
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

9.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Authors:  C Y Chu; B K Liu; D Watson; S S Szu; D Bryla; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.